Emergent BioSolutions, a biopharmaceutical solutions company with a location in Lansing, is looking to purchase a large manufacturing facility in Maryland to accommodate production rates that its two facilities in Frederick, MD cannot meet.
According to excerpts from the article:
The Frederick facilities, consisting of two 145,000-sq-ft buildings, were acquired in 2004 and 2006. Emergent says that the cost involved in building one of the sites to required production specs would be higher than the purchase price of the new manufacturing site. The new plant will include several suites suitable for cGMP manufacturing of multiple products as well as space for process development and administrative functions.
The company will thus be able to offer the U.S. government another site where recombinant protective antigen (rPA) anthrax vaccine, which is under Phase II development, can be produced. It also frees up building 55 in Lansing, MI, for BioThrax® scale-up; BioThrax is the only vaccine licensed by the FDA for the prevention of anthrax disease.
Emergent says that it is still in negotiations to purchase a laboratory in Gaithersburg, MD. It includes space for product development, process development, assay development, and administrative functions.
Read the entire article here.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.